Sign In
Buy MRNA
$59.81
+0.640 (+1.08%)
At Close: Aug 10, 2026
Moderna announces executive changes ahead of potential launches
08:37am, Tuesday, 16'th Jun 2026
Moderna appointed a new chief commercial officer and widened its president's role to oversee certain franchises, the vaccine maker said on Tuesday, as it prepares for potential product launches
Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028
07:30am, Tuesday, 16'th Jun 2026
Dr. Stephen Hoge, President of Moderna, to Assume an Expanded Role With Operational Oversight of the Company's Infectious Disease, Intismeran and Rare Disease Franchises Ester Banque to Join Moderna a
Moderna, Inc. (MRNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
05:32pm, Tuesday, 09'th Jun 2026
Moderna, Inc. (MRNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Does Moderna Need to Start Making Money?
07:11am, Tuesday, 09'th Jun 2026
Moderna is losing billions of dollars per year. The company has several promising new products that should be coming to the market within the next few years.
Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%[1] The INTERCEPT-Lynch trial is part of a scientific collaboration between the Universi
Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026
02:45am, Wednesday, 03'rd Jun 2026
This biotech is making solid progress with several pipeline candidates. It could have a stronger lineup of approved products within a few years.
Moderna Launches Moderna Direct with “eCommerce Powered by FFF Enterprises™”
04:34pm, Tuesday, 02'nd Jun 2026
eCommerce Powered by FFF Enterprises™ delivers an enhanced ordering experience for Moderna customers. eCommerce Powered by FFF Enterprises™ delivers an enhanced ordering experience for Moderna cus
MRNA Partners With CEPI to Develop Vaccine for Bundibugyo Ebolavirus
12:01pm, Tuesday, 02'nd Jun 2026
Moderna gains up to $50M from CEPI to advance a Bundibugyo ebolavirus vaccine as the partnership expands amid an ongoing Ebola outbreak.
Moderna to Present at Upcoming Conference in June 2026
07:00am, Tuesday, 02'nd Jun 2026
CAMBRIDGE, MA / ACCESS Newswire / June 2, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Goldman Sachs 47th Annual Global Healthca
Moderna, Inc. (MRNA) Discusses Intismeran mRNA Immunotherapy and Phase II KEYNOTE-942 Oncology Data Transcript
01:04am, Tuesday, 02'nd Jun 2026
Moderna, Inc. (MRNA) Discusses Intismeran mRNA Immunotherapy and Phase II KEYNOTE-942 Oncology Data Transcript
Moderna Reports Strong 5-Year Cancer Vaccine Data, Expands CEPI Partnership; Stock Falls
12:39pm, Monday, 01'st Jun 2026
Moderna, Inc. (NASDAQ:MRNA) stock is trading lower on Monday.
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurr
Moderna partners with global health coalition to develop Bundibugyo Ebola vaccine
05:37am, Monday, 01'st Jun 2026
Moderna said on Monday it has partnered with the Coalition for Epidemic Preparedness Innovations to develop a potential vaccine against Bundibugyo ebolavirus, the strain linked to the ongoing �
Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
05:00am, Monday, 01'st Jun 2026
Coalition for Epidemic Preparedness Innovations funding builds on Moderna's prior filovirus research and supports preclinical development and Phase 1 clinical evaluation CAMBRIDGE, MA / ACCESS Newswir
Moderna, Inc. (MRNA) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
03:54am, Saturday, 30'th May 2026
Moderna, Inc. (MRNA) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
